The New Orleans-based 5th U.S. Circuit Court of Appeals has granted a stay that effectively halts the distribution of mifepristone via mail. Under the new ruling, the drug must be provided in person at medical offices, clinics, or hospitals. This decision reverses a regulatory shift that, according to some sources, had made telehealth and mail-order prescriptions a major way for patients to obtain medication abortions, particularly in states where the practice is banned or heavily restricted.
The legal challenge was driven by the state of Louisiana, which argued that the FDA’s allowance of mail-order prescriptions undermined state law. According to the court ruling, Every abortion facilitated by FDA’s action cancels Louisiana’s ban on medical abortions and undermines its policy that ‘every unborn child is human being from the moment of conception and is, therefore, a legal person,’
the opinion states.
The 5th Circuit Reinstates In-Person Requirements
The ruling follows a legal battle over the FDA’s regulatory authority. During the Covid pandemic, the FDA under President Joe Biden temporarily removed the requirement for mifepristone to be dispensed only in person. That change was made permanent in 2023. Louisiana challenged this regulation, alleging that the data supporting the shift was nonexistent or flawed and that the policy created safety risks.
A district court judge had previously ruled that Louisiana was likely to win its challenge and was suffering irreparable harm. However, that judge declined to immediately undo the regulations. The 5th Circuit Court of Appeals stepped in to grant the stay requested by Louisiana’s attorney general and a woman who claimed she was coerced into taking the pills.
“The district court agreed that Louisiana was likely to win its challenge to the mifepristone regulation and was suffering irreparable harm from it,” Circuit Judge Stuart Kyle Duncan wrote in the panel’s opinion. “Nonetheless, the court declined to stay the regulation based on its balancing of the equities and the public interest. Louisiana appealed to our court and sought a stay pending appeal. We grant the stay.” Stuart Kyle Duncan, Circuit Judge
Mifepristone, approved in 2000 as a safe and effective method to end early pregnancies, is typically used in combination with a second drug, misoprostol. While the drug has been used for more than 25 years, the current ruling forces a return to a more restrictive distribution model.
Telemedicine and the Post-Dobbs Landscape
Since the 2022 Supreme Court decision that overturned Roe v. Wade, the landscape of abortion access has shifted toward telehealth. With many states enforcing total or near-total bans, mail-order prescriptions became a key to maintaining access for patients unable to travel to clinics in other states. The 5th Circuit’s decision restricts that specific distribution method for mifepristone.
Julia Kaye, a senior staff attorney for the Reproductive Freedom Project of the ACLU, stated that the removal of telehealth options will disproportionately impact the most vulnerable populations. She noted that the ruling will affect access to abortion and miscarriage care in every state in the nation.
“When telemedicine is restricted, rural communities, people with low incomes, people with disabilities, survivors of intimate partner violence and communities of color suffer the most.” Julia Kaye, ACLU
Kaye further noted that Anti-abortion politicians have just made it much harder for people everywhere in the country to get a medication that abortion and miscarriage patients have been safely using for more than 25 years,
as reported by NBC News.
FDA Safety Reviews and Legal Uncertainty
The ruling comes while the agency’s processes are under scrutiny. Under President Donald Trump, FDA officials have stated that the agency is conducting a new safety review of mifepristone. This review was ordered by the president, but the timeline for its completion remains unknown.
The court highlighted this lack of clarity in its ruling, noting that the FDA could not say when that review might be complete and admitted it was still collecting data,
according to NPR. In January, the FDA had requested that Louisiana’s lawsuit be paused until this safety review was finished, but the appeals court has now moved forward with the stay regardless of the review’s status.
Some industry leaders have expressed alarm over the court’s decision. Evan Masingill, CEO of GenBioPro, a company that manufactures a generic version of mifepristone, said the company is committed to keeping the medication accessible. He described the court’s decision as an attempt to ignore the FDA’s rigorous science and decades of safe use of mifepristone
in a case he characterized as being pursued by extremist abortion opponents.
The Path Toward the Supreme Court
The decision by the 5th Circuit is expected to trigger an appeal to the U.S. Supreme Court. Because the ruling applies nationwide, it creates an immediate shift in how medication abortions are administered across the country. Patients who previously relied on telehealth consultations and home delivery must now find clinics capable of providing the drug in person.
This shift happens as medication abortion continues to represent more than half of all abortions in the U.S. While peer-reviewed research and multiple studies have indicated that medication abortion is safe and effective when taken at home following a clinician’s consultation, those findings are currently being superseded by the court’s requirement for physical clinical presence.
What to watch now is whether the Supreme Court will grant an emergency stay to restore mail-order access or if the in-person requirement will remain the law of the land while the safety review and the broader legal challenge proceed. The outcome will determine whether the FDA’s regulatory updates since 2000 are viewed as a matter of medical safety or a violation of state sovereignty.
